Hutchison China MediTech Limited Company Profile (LON:HCM)

About Hutchison China MediTech Limited (LON:HCM)

Hutchison China MediTech Limited logoHutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Alternative Medicine
  • Sub-Industry: N/A
  • Symbol: LON:HCM
  • CUSIP: N/A
  • Web: www.chi-med.com/
Capitalization:
  • Market Cap: £2.1 billion
  • Outstanding Shares: 60,642,000
Average Prices:
  • 50 Day Moving Avg: GBX 3,421.97
  • 200 Day Moving Avg: GBX 2,850.76
  • 52 Week Range: GBX 1,760 - GBX 3,520
P/E:
  • Trailing P/E Ratio: 177.04
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £216.08 million
  • Price / Sales: 9.74
  • Book Value: GBX 3.04 per share
  • Price / Book: 11.41
Profitability:
  • EBIDTA: ($44,390,000.00)
  • Net Margins: 10.54%
  • Return on Equity: 12.27%
  • Return on Assets: 7.05%
Misc:
  • Average Volume: 8,269 shs.
 
Frequently Asked Questions for Hutchison China MediTech Limited (LON:HCM)

What is Hutchison China MediTech Limited's stock symbol?

Hutchison China MediTech Limited trades on the London Stock Exchange (LON) under the ticker symbol "HCM."

When will Hutchison China MediTech Limited make its next earnings announcement?

Hutchison China MediTech Limited is scheduled to release their next quarterly earnings announcement on Sunday, July, 30th 2017. View Earnings Estimates for Hutchison China MediTech Limited.

Where is Hutchison China MediTech Limited's stock going? Where will Hutchison China MediTech Limited's stock price be in 2017?

2 brokers have issued twelve-month price targets for Hutchison China MediTech Limited's stock. Their forecasts range from GBX 3,530 to GBX 3,530. On average, they expect Hutchison China MediTech Limited's share price to reach GBX 3,530 in the next year. View Analyst Ratings for Hutchison China MediTech Limited.

Who are some of Hutchison China MediTech Limited's key competitors?

Who are Hutchison China MediTech Limited's key executives?

Hutchison China MediTech Limited's management team includes the folowing people:

  • Simon To, Executive Chairman of the Board
  • Christian Hogg, Chief Executive Officer, Executive Director
  • Chig Fung Cheng, Chief Financial Officer, Executive Director
  • Weiguo Su Ph.D., Executive Director
  • Edith Shih, Company Secretary, Non-Executive Director
  • Dan Eldar, Non-Executive Director
  • Paul Rutherford Carter, Senior Independent Non-Executive Director
  • Karen Jean Ferrante M.D., Non-Executive Independent Director
  • Graeme Allan Jack, Independent Non-Executive Director

How do I buy Hutchison China MediTech Limited stock?

Shares of Hutchison China MediTech Limited and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hutchison China MediTech Limited's stock price today?

One share of Hutchison China MediTech Limited stock can currently be purchased for approximately GBX 3,470.


MarketBeat Community Rating for Hutchison China MediTech Limited (LON HCM)
Community Ranking:  4.4 out of 5 (   )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hutchison China MediTech Limited (LON:HCM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 3,530

Analysts' Ratings History for Hutchison China MediTech Limited (LON:HCM)
Show:
DateFirmActionRatingPrice TargetDetails
6/30/2017Beaufort SecuritiesReiterated RatingBuyView Rating Details
6/22/2017Panmure GordonReiterated RatingBuyGBX 3,530View Rating Details
4/11/2016Stifel NicolausInitiated CoverageBuyView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Hutchison China MediTech Limited (LON:HCM)
Earnings by Quarter for Hutchison China MediTech Limited (LON:HCM)
Earnings History by Quarter for Hutchison China MediTech Limited (LON HCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2017N/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hutchison China MediTech Limited (LON:HCM)
Current Year EPS Consensus Estimate: $-0.25 EPS

Dividends

Dividend History for Hutchison China MediTech Limited (LON:HCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hutchison China MediTech Limited (LON:HCM)
Insider Trades by Quarter for Hutchison China MediTech Limited (LON:HCM)
Insider Trades by Quarter for Hutchison China MediTech Limited (LON:HCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2017Paul Rutherford CarterInsiderBuy2,800GBX 2,637£73,836
11/21/2016Michael HowellInsiderSell3,000GBX 1,890£56,700
10/28/2016Michael HowellInsiderSell2,500GBX 1,860£46,500
10/26/2016Michael HowellInsiderSell3,000GBX 1,850£55,500
10/25/2016Michael HowellInsiderSell1,000GBX 1,840£18,400
10/24/2016Michael HowellInsiderSell339GBX 1,825£6,186.75
10/7/2016Michael HowellInsiderSell15,000GBX 1,790£268,500
8/4/2016Nash,ChristopherInsiderBuy42GBX 1,899£797.58
10/20/2015Nash,ChristopherInsiderBuy4,512GBX 2,195£99,038.40
4/21/2015Christopher NashInsiderBuy1,388GBX 1,800£24,984
4/15/2015Simon ToInsiderBuy28,000GBX 1,585£443,800
4/10/2015Simon ToInsiderBuy25,000GBX 1,421.50£355,375
4/7/2015Edith ShihInsiderBuy2,000GBX 1,385£27,700
4/2/2015Simon ToInsiderBuy10,000GBX 1,385£138,500
4/1/2015Edith ShihInsiderBuy15,000GBX 1,365£204,750
3/30/2015Edith ShihInsiderBuy13,000GBX 1,300£169,000
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hutchison China MediTech Limited (LON:HCM)
Latest Headlines for Hutchison China MediTech Limited (LON:HCM)
Source:
DateHeadline
americanbankingnews.com logoHutchison China MediTech Limited (LON:HCM) Set to Announce Earnings on Sunday
www.americanbankingnews.com - July 23 at 4:26 AM
americanbankingnews.com logoHutchison China MediTech Limited's (LON:HCM) Buy Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - July 1 at 1:50 PM
businesswire.com logoChi-Med to Announce 2017 Half-Year Financial Results - Business Wire (press release)
www.businesswire.com - July 1 at 12:33 AM
businesswire.com logoChi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma - Business Wire (press release)
www.businesswire.com - June 29 at 5:01 AM
americanbankingnews.com logoPanmure Gordon Reaffirms Buy Rating for Hutchison China MediTech Limited (HCM)
www.americanbankingnews.com - June 22 at 3:00 PM
finance.yahoo.com logoChi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China
finance.yahoo.com - June 22 at 9:05 AM
businesswire.com logoChi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO
www.businesswire.com - June 5 at 8:43 PM
streetinsider.com logoChi-Med (HCM) to Present Clinical Data at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 10:09 AM
americanbankingnews.com logoHutchison China MediTech Limited (HCM) Price Target Increased to GBX 3,530 by Analysts at Panmure Gordon
www.americanbankingnews.com - May 18 at 6:40 AM
finance.yahoo.com logoHutchison China MediTech Ltd. – Value Analysis (LONDON:HCM) : May 15, 2017
finance.yahoo.com - May 16 at 11:23 AM
finance.yahoo.com logoHutchison China MediTech Ltd. breached its 50 day moving average in a Bearish Manner : HCM-GB : May 12, 2017
finance.yahoo.com - May 12 at 6:17 PM
prnewswire.com logoEdison Issues Outlook on Hutchison China MediTech (HCM)
www.prnewswire.com - May 11 at 6:14 PM
reuters.com logoBRIEF-Hutchison China Meditech Ltd says may offer to sell in one or more offerings ADS representing ordinary shares
www.reuters.com - April 3 at 1:23 PM
seekingalpha.com logoHutchison China Meditech (HCM) Presents At Deutsche Bank Depositary Receipts Virtual Investor Conference - Slideshow
seekingalpha.com - March 24 at 5:43 PM
americanbankingnews.com logoHutchison China MediTech Limited (HCM) Insider Paul Rutherford Carter Buys 2,800 Shares
www.americanbankingnews.com - March 20 at 12:12 PM
finance.yahoo.com logoChi-Med: Grant of Awards under Long Term Incentive Plan
au.finance.yahoo.com - March 16 at 3:42 PM
americanbankingnews.com logoHutchison China MediTech Limited’s (HCM) “Buy” Rating Reaffirmed at Beaufort Securities
www.americanbankingnews.com - March 15 at 12:25 AM
biz.yahoo.com logoFull Year 2016 Hutchison China MediTech Ltd Earnings Release - 03:00 am ET
biz.yahoo.com - March 13 at 11:09 AM
uk.finance.yahoo.com logoChi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of European Neuroendocrine Tumor Society
uk.finance.yahoo.com - March 10 at 10:14 AM
ft.com logo[$$] Chi-Med eyes global markets after cancer trial success
www.ft.com - March 3 at 5:37 PM
seekingalpha.com logoChi-Med Looks Outside Its Comfort Zone - Seeking Alpha
seekingalpha.com - February 22 at 5:47 PM
uk.finance.yahoo.com logoChi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma
uk.finance.yahoo.com - February 20 at 10:50 AM
finance.yahoo.com logoHutchison China Meditech Limited: Initiates Phase I of Novel FGFR Inhibitor HMPL-453 - Yahoo Finance
finance.yahoo.com - February 14 at 4:40 AM
streetinsider.com logoForm SC 13G Hutchison China MediTech Filed by: CK Hutchison Holdings Ltd
www.streetinsider.com - February 8 at 6:17 PM
finanznachrichten.de logoHUTCHISON CHINA MEDITECH LIMITED
www.finanznachrichten.de - February 1 at 4:23 AM
finance.yahoo.com logoHutchison China Meditech Limited: Fruquintinib Phase I/II Clinical Data at ASCO GI - Yahoo Finance
finance.yahoo.com - January 17 at 3:38 PM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With Hematological Malignancies
www.streetinsider.com - January 10 at 4:24 AM
streetinsider.com logoHutchison China MediTech (HCM) Begins Phase 1 Of HMPL-523 Clinical Trials In China On Patients With ... - StreetInsider.com
www.streetinsider.com - January 10 at 4:24 AM
bloomberg.com logoChina’s Airpocalypse Paves a Path for New Cancer Medicines
www.bloomberg.com - January 5 at 6:36 PM
streetinsider.com logoForm 6-K Hutchison China MediTech For: Dec 31 - StreetInsider.com
www.streetinsider.com - December 30 at 6:02 PM
finance.yahoo.com logoChi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
au.finance.yahoo.com - December 6 at 10:38 AM
finance.yahoo.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)
finance.yahoo.com - November 29 at 4:50 PM
finance.yahoo.com logoChi-Med to Present Data from Proof-of-Concept Clinical Trials for Fruquintinib and Epitinib at the 17th World Conference on Lung Cancer (“WCLC”)
finance.yahoo.com - November 29 at 4:50 PM
businesswire.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting - Business Wire (press release)
www.businesswire.com - November 14 at 9:28 AM
uk.finance.yahoo.com logoChi-Med Presents Phase I Clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 ACR/ARHP Annual Meeting
uk.finance.yahoo.com - November 14 at 9:28 AM

Social

Social activity is not available for this stock.

Chart

Hutchison China MediTech Limited (HCM) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff